From Theory to Practice: Applying Current Clinical Knowledge and Treatment Strategies to the Care of Hemophilia A Patients With Inhibitors

Abstract 

Two bypassing agents are currently available to circumvent the need for factor FVIII in hemophilia A patients with inhibitors: the activated prothrombin complex FEIBA VH and recombinant activated factor VII (NovoSeven®). Both products are highly effective in controlling bleeding in the presence of inhibitory alloantibodies, yet their hemostatic efficacy can be unpredictable. As the results of the FEIBA NovoSeven® Comparative (FENOC) study illustrate, patients may respond better to one bypassing agent than the other. Furthermore, guidelines from an expert panel reflect that responsiveness to bypassing therapy may change from one bleed to the next in the same patient and even from hour to hour during the course of a single bleeding event. These findings underscore the need to have both bypassing products available to treat bleeding episodes in inhibitor patients, to frequently evaluate the efficacy of hemostasis during the course of a bleeding event, and to switch products early if the response to treatment is unsatisfactory. © 2008 Elsevier Ltd. All rights reserved.

Key Words:  Hemophilia , Inhibitors , Discordant pairs , FEIBA , NovoSeven

No full text is available. To read the body of this article, please view the PDF online.